Scinai Immunotherapeutics
SCNI
12 hedge funds and large institutions have $2.61M invested in Scinai Immunotherapeutics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
278% more capital invested
Capital invested by funds: $689K → $2.61M (+$1.92M)
50% more funds holding
Funds holding: 8 → 12 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$106K |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$68.5K |
| 3 |
Renaissance Technologies
New York
|
+$65.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$56.6K |
| 5 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$12.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$139K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $1.92M | +$2.26M | +3,590 | New |
|
|
2
Renaissance Technologies
New York
| $200K | +$65.4K | +104 | +39% |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $192K | +$56.6K | +90 | +33% |
|
|
VIA
4
Vantage Investment Advisors
State College,
Pennsylvania
| $113K | +$12.6K | +20 | +11% |
|
|
5
HighTower Advisors
Chicago,
Illinois
| $91K | +$106K | +168 | New |
|
|
PVH
6
Psagot Value Holdings
Tel Aviv,
Israel
| $58K | +$68.5K | +109 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $13K | – | – | – |
|
8
Morgan Stanley
New York
| $8K | +$6.92K | +11 | +220% |
|
9
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
|
EWM
10
Edge Wealth Management
New York
| $1K | – | – | – |
|
|
CA
11
Calton & Associates
Tampa,
Florida
| $1K | +$1.26K | +2 | New |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$139K | -194 | Closed |
|
|
AS
13
Altshuler Shaham
Tel Aviv,
Israel
| – | +$3.77K | +6 | New |
|
SCNI Hedge Fund Activity: Q4 2017 in Review
12 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2017, worth a combined $2.61M — up 278% from $689K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SCNI positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $106K. The largest seller was Sabby Management, exiting entirely with an estimated $139K sold.
- 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2017, up from 8 in Q3 2017.
- Funds reported $2.61M of Scinai Immunotherapeutics stock for Q4 2017, up 278% quarter-over-quarter.
- 5 funds opened new Scinai Immunotherapeutics positions in Q4 2017 and 1 closed out, a net change of +4 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2017 was HighTower Advisors, an estimated $106K added.
- The largest Scinai Immunotherapeutics seller in Q4 2017 was Sabby Management, an estimated $139K sold.
Based on aggregated 13F filings for Q4 2017.